NBIX

#615
Neurocrine Biosciences, Inc. - Common Stock
158.3 0 USD
+1.22%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
158.30
158.30
Faixa anual
1.55
162.39
Mudança diária
+1.22%
Mudança mensal
+22.00%
Mudança em 6 meses
+4.04%
Mudança anual
+9.17%
Fechamento anterior
156.3 9
Open
158.3 0
Mínimo
158.3 0
High
158.3 0
Volume
309
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 15.92 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Fabricantes de medicamentos - especializados e genéricos
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
30.37
Índice preço/fluxo de caixa
5.08

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Notícias